Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18191 | 0.89 | CYP2C19 (0.42) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL8858515 | 0.85 | CYP2C19 (0.40) | CYP2C19 | |
| Methyl Alcohol SCHEMBL4271767 | 0.81 | CYP2C19 (0.38) | CYP2C19 | |
| Ethylene SCHEMBL4765785 | 0.81 | CYP2C19 (0.38) | CYP2C19 | |
| Fluoride SCHEMBL732880 | 0.81 | CYP2C19 (0.38) | CYP2C19 | |
| Fluoride SCHEMBL15313130 | 0.81 | CYP2C19 (0.38) | CYP2C19 | |
| Tetrahydrothiophene SCHEMBL2638503 | 0.80 | — | — | |
| SCHEMBL12039859 | 0.79 | TSHR (0.40) | CYP2C19 | |
| SCHEMBL12039860 | 0.79 | TSHR (0.40) | CYP2C19 | |
| SCHEMBL12039856 | 0.79 | TSHR (0.40) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019012001-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-8735426-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275044-A1 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | TRPV1, TRPV2, TRPV3 | CYP2C19 1449/4885 |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | CYP2C19 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.